Illumina Inc. and Nashville Biosciences, LLC (NashBio) announced on March 19, 2025, that the Alliance for Genomic Discovery (AGD) initiative has completed the sequencing of 250,000 whole genomes. This milestone was achieved faster than the original projection of late 2025, highlighting the efficiency of the collaboration.
The resulting AGD dataset, one of the largest and most comprehensive clinical genomic datasets of its kind, is now available to the alliance's eight biopharma members through Illumina Connected Analytics. This resource is being leveraged to accelerate drug target discovery, therapeutic research, and clinical development.
De-identified DNA samples from Vanderbilt University Medical Center's BioVU® biobank were sequenced by deCODE genetics using Illumina's end-to-end sequencing workflow, including the DRAGEN analysis pipeline. The next phase of AGD plans to expand the dataset by adding multiomic layers, further enriching its value for life sciences exploration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.